Mediastinal Metastases in Bronchogenic Carcinoma: Influence of Postoperative Irradiation, Cell Type, and Location

https://doi.org/10.1016/S0003-4975(10)60786-2Get rights and content

Abstract

A 17-year experience with 136 patients with bronchogenic carcinoma and mediastinal metastases is reported. Six died postoperatively. Postoperative mediastinal irradiation was given to 110 patients surviving curative resection who had evidence of tumor spreading to the mediastinal lymph nodes. The remaining 20 patients did not receive radiation therapy.

Of the 136 patients, 29 (21.3%) lived 5 years free from disease and 9 survived 10 or more years. Of the 110 patients who survived operation and underwent irradiation, 29 (26.4%) survived 5 years. None of the 20 patients not receiving radiation therapy lived 5 years. Of the patients who underwent irradiation, 18 of the 50 patients with squamous cell carcinoma survived 5 years, while only 7 of 55 with adenocarcinoma survived 5 years.

We do not believe that the discovery of mediastinal lymph node involvement in bronchogenic carcinoma is a contraindication to pulmonary resection. As in our previous reports, histological cell type has proved to be an important indicator of absolute survival. Patients with squamous cell carcinoma had an absolute 5-year survival of 33.9%, while the patients with adenocarcinoma had an absolute survival of 12.3%.

The level of lymph node metastasis has an influence on prognosis as well. Patients with subcarinal lymph node metastases had a lower survival than patients with superior mediastinal involvement.

References (12)

There are more references available in the full text version of this article.

Cited by (104)

  • Non-Small Cell Lung Cancer

    2015, Clinical Radiation Oncology
  • Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer

    2013, European Journal of Cancer, Supplement
    Citation Excerpt :

    Using TNM-7, corresponding rates were 16%, 23%, 37%, 39% and 30%, respectively, and there about 10–15% ‘stage shifters’ [14,15]. Several retrospective studies, contemporaneous to the studies included in the meta-analysis, have shown that the risk of local recurrence could be reduced by PORT (25–35%) in historical comparisons [16–22]. However, this finding was not corroborated by most randomised trials.

  • Non-Small Cell Lung Cancer

    2012, Clinical Radiation Oncology: Third Edition
  • Non–Small Cell Lung Cancer

    2011, Clinical Radiation Oncology, Third Edition
  • Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)

    2007, Chest
    Citation Excerpt :

    The role of postoperative radiation therapy in patients with NSCLC has been debated for many years. The ability of postoperative radiation therapy in moderate doses, 45 to 55 Gy, to eradicate microscopic residual disease and reduce rates of local recurrence was strongly suggested in several early single-institution trials.18, 19, 20 What has remained controversial is whether the reduction in locoregional recurrence also leads to an improvement in overall survival.

View all citing articles on Scopus
View full text